This handout is for diabetes-related foot disease (ulcer, infection, osteomyelitis). Your care team identified this based on: open ulcer / wound on foot in patient with diabetes (iwgdf 2023).
Other reasons your team may use this plan: foot redness / warmth / swelling — suspected infection (idsa 2012 lipsky); new foot pain or loss of sensation — neuropathy or ischemia (iwgdf 2023); foot x-ray findings of osteomyelitis or charcot (iwgdf 2023).
Take these medications exactly as prescribed. Do not stop or change a dose without talking to your provider.
| Medication | Starting dose | How | When | What it does |
|---|---|---|---|---|
| cephalexin | 500 mg PO QID | PO | q6h × 7–14 days | IDSA 2023 — first-line MSSA/strep coverage |
| dicloxacillin | 500 mg PO QID | PO | q6h × 7–14 days | IDSA — alternative anti-staph penicillin |
| clindamycin | 300–450 mg PO QID | PO | q6h × 7–14 days | PCN-allergic; check local D-test for inducible MRSA resistance |
| doxycycline | 100 mg PO BID | PO | q12h × 7–14 days | IDSA — covers CA-MRSA + good tissue penetration |
| trimethoprim-sulfamethoxazole | 1 DS tab (160/800) PO BID | PO | q12h × 7–14 days | IDSA — covers CA-MRSA; renal dose; SJS warning + warfarin/sulfonylurea interactions |
Plan: IDSA / IWGDF 2023 — severity-tiered empirical antibiotic regimen for diabetic foot infection
Use these zones to know what to do based on how you feel.
Call 911 or go to the nearest emergency room right away if you have:
Multidisciplinary clinic q1–4 wk; podiatry + wound care + endocrinology + vascular; preventive education (daily inspection, footwear, hygiene); annual screening (monofilament, ABI/TBI, foot exam); secondary prevention after healed ulcer
Guideline: IDSA / IWGDF 2023 — Diagnosis and treatment of diabetes-related foot infection + IWGDF 2023 prevention/management practical guidelines + ADA Standards of Care 2026 + SVS / ESVS / SCAI 2024 (CLTI) + WOCN 2022